PCP
EW icon

Pacific Capital Partners’s Edwards Lifesciences EW Stock Holding History

Pacific Capital Partners’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-22,500
Closed -$1.76M – 39
2025
Q2 		$1.76M Buy
+22,500
New +$1.68M 1.65% 20

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return

Pacific Capital Partners's EW Position: Q3 2025 in Review

Pacific Capital Partners sold out of Edwards Lifesciences (EW) in Q3 2025, closing a stake of 22,500 shares — an estimated $1.76M sold.

Pacific Capital Partners first reported a position in EW in Q2 2025 and held it in 1 quarter. The position peaked at $1.76M in Q2 2025. 1,253 funds tracked by Wall St. Rank hold EW as of Q3 2025.

  • Pacific Capital Partners reported no remaining Edwards Lifesciences position as of Q3 2025 after selling out during the quarter.
  • Pacific Capital Partners sold 22,500 Edwards Lifesciences shares in Q3 2025, an estimated $1.76M.
  • Pacific Capital Partners first reported a position in Edwards Lifesciences in Q2 2025 and held it in 1 quarter.
  • Pacific Capital Partners's Edwards Lifesciences position peaked at $1.76M in Q2 2025.
  • 1,253 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2025.

Based on Pacific Capital Partners's 13F filing for Q3 2025, filed 27 Oct 2025.